AstraZeneca Pharma India Q2 profit rises 14.9% to Rs 62.3 crore
In short
AstraZeneca Pharma India said its Q2 net profit rose 14.9% year-on-year to ₹62.3 crore. Revenue grew 30.4% to ₹729 crore, and EBITDA rose 26.7% to ₹95 crore, with margin at 13.1%.
The company also got regulatory approvals for two drugs, which could support its business in cancer and rare disease treatments.
What the reporting says
AstraZeneca Pharma India reported a 14.9% year-on-year rise in Q2 net profit to ₹62.3 crore, while revenue increased 30.4% to ₹729 crore. EBITDA grew 26.7% to ₹95 crore and the margin stood at 13.1%. The company also secured regulatory approvals for trastuzumab deruxtecan across multiple HER2-positive breast cancer treatment settings and benralizumab for hypereosinophilic syndrome.
Why it matters
AstraZeneca Pharma India reported stronger Q2 numbers, with net profit up 14.9% to ₹62.3 crore and revenue up 30.4% to ₹729 crore. EBITDA also rose to ₹95 crore, with a 13.1% margin. The company additionally received approvals for trastuzumab deruxtecan and benralizumab, which may support future sales in oncology and rare disease segments.